Citation Tools

Download PDFPDF

402 Study design and rationale for the efficacy and safety assessment of daxdilimab, a selective plasmacytoid dendritic cell depleter, in a phase 2 trial of patients with moderate-to-severe primary discoid lupus erythematosus

Download to a citation manager

Cite this article as:
Knight AK, Larson D, Wang L, et al
402 Study design and rationale for the efficacy and safety assessment of daxdilimab, a selective plasmacytoid dendritic cell depleter, in a phase 2 trial of patients with moderate-to-severe primary discoid lupus erythematosus